A Trial to Investigate the Non-inferiority of Pegloticase Administered Every 4 Weeks (Q4W) With MTX Compared With Every 2 Weeks (Q2W) With MTX in Participants With Uncontrolled Refractory Gout
4상
완료
NCT06229145
| 대상 질환 | Gout |
|---|
| 임상 단계 | 4상 |
|---|
| 스폰서 | Amgen |
|---|
| 상태 | 완료 |
|---|
| 참여자 수 | 262 명 |
|---|
| 중재(약물) | Pegloticase, Methotrexate |
|---|
| 시작일 | 2024년 3월 18일 |
|---|
| 완료일 | 2025년 7월 30일 |
|---|
| 결과 공개일 | 2026년 7월 1일 |
|---|
요약
The study consists of 24-week double-blind trial to evaluate the non-inferiority of the efficacy and safety of pegloticase Q4W with MTX versus pegloticase Q2W with MTX, followed by a 24-week open-label extension of pegloticase Q4W with MTX, in participants with uncontrolled refractory gout. The main objective of the study is to evaluate the effect of pegloticase 16 mg administered Q4W with MTX versus pegloticase 8 mg administered Q2W with MTX, on the response rate during Month 6, as measured by the sustained normalization of sUA to \< 6 mg/dL for at least 80% of the time.
Percentage of Serum Uric Acid (sUA) Responders (sUA < 6 mg/dL) During Month 6
Month 6 (Weeks 20, 21, 22, 23, and 24) · percentage of participants
| Pegloticase 8mg Q2W + MTX | 70.8 percentage of participants |
|---|
| Pegloticase 16mg Q4W + MTX | 56.5 percentage of participants |
|---|
| p-value | 0.10 |
|---|
| Response rate difference | 12.7 (95% CI 1.2–24.1) |
|---|
BENITIONS에서 보기
ClinicalTrials.gov 원문 보기
전체 임상
이 페이지는 ClinicalTrials.gov의 공개 데이터를 정리한 것입니다. 의학적 조언이 아니며 투자 권유나 자문도 아닙니다. 반드시 전문의와 상담하세요.